Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: PTSC sold 4% stake in Talis? explanation

many investors in ventures have specific non-dilution clauses that are activated when new money is raised.

PTSC's investment trigerred a right for prior investors to retain a level of ownership.

Likewise certain investors wish to see management invest capital and the PTSC Talis agreement might have included this clause - although not likely since it would have been noted in teh first release - most likely the former scenario that upon closing Talis contacted prior investors and some or all exercised an anti-dilutuion right.





1
Aug 06, 2008 06:12AM
Share
New Message
Please login to post a reply